Analysts have modestly raised their price target for Smith & Nephew from $14.37 to $14.50. This reflects incremental adjustments to fair value and slightly revised underlying financial assumptions.
What's in the News
- Smith & Nephew maintained earnings guidance for 2025, expecting trading profit margin to expand to 19.0%–20.0% and accounting for a net impact of $15–$20 million from tariffs in 2025, as previously outlined (Corporate Guidance).
- New comparative study findings indicate Smith+Nephew's PICO single-use negative pressure wound therapy (sNPWT) device significantly reduces wound dehiscence, hospital length of stay, and costs in orthopedic and cardiovascular surgeries compared to alternative devices (Product-Related Announcements).
- Sectra expanded its pre-operative planning solution to include Smith+Nephew's 3D templates for orthopedic trauma. This enhances patient-specific treatments and operational efficiency in surgery (Client Announcements).
- Recent evidence and market updates support wider adoption of the REGENETEN Bioinductive Implant for rotator cuff and extra-articular ligament repairs. Clinical studies show reduced re-tear rates and improved patient outcomes (Product-Related Announcements).
- Smith+Nephew launched the CENTRIO Platelet-Rich-Plasma (PRP) System for chronic wound management. The system supports natural healing and is now available through a new distribution agreement in the United States (Product-Related Announcements).
Valuation Changes
- The Consensus Analyst Price Target has risen slightly from £14.37 to £14.50, reflecting incremental upward adjustments in fair value.
- The Discount Rate has decreased marginally, moving from 8.53% to 8.53%.
- Revenue Growth projections have edged down slightly from 5.41% to 5.40%.
- The Net Profit Margin has declined modestly from 13.23% to 13.22%.
- The Future P/E Ratio has increased somewhat from 23.03x to 23.40x.
Have other thoughts on Smith & Nephew?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.